Market By Dosages, Formulation And Geography | Forecast 2019-2027
A detailed analysis by Triton has found that the global hyperphosphatemia drugs market is expected to display a positive market trend over the forecast period of 2019-2027, exhibiting a CAGR of 16.61%. The market was assessed to be worth $2873.67 million in the year 2018 and is predicted to generate a revenue of approximately $11480.07 million by the year 2027.
Report scope can be customized per your requirements. Request For Customization
Hyperphosphatemia is a condition of electrolyte disturbance in the body, with an abnormal increase in the blood’s phosphate levels. Generally, calcium levels are reduced (hypocalcemia) because the phosphate precipitates with the calcium in the tissues. The average levels of phosphorus should ideally range from 0.81 mmol per liter to 1.45 mmol per liter.
Hyperphosphatemia is diagnosed by the process of measuring the phosphate concentration in the blood. A phosphate concentration >1.46 mmol/L (4.5 mg/dL) indicates the presence of hyperphosphatemia. However, further tests may be necessary to identify the root cause of the elevated phosphate levels. The formulation of hyperphosphatemia drugs is applied extensively for different purposes. Calcium-based phosphate binders took the place of aluminum-based phosphate binders and have been used since the 1990s. Calcium-based phosphate binders are also used as calcium supplements. Aluminum-based phosphate binders have been used for a long time for treating hyperphosphatemia in dialysis patients. Also, the magnesium-based phosphorus binders are prominently used in the treatment of hyperphosphatemia conditions in all dialysis patients. Iron-based phosphate binders such as sevelamer are impactful in curing hyperphosphatemia and anemia. These binders are associated with an iron surplus in the body.
The global hyperphosphatemia drugs market report covers the present market situation and the growth prospects of the global hyperphosphatemia drugs market for the period of 2019-2027 and considers the revenue generated due to the sales of hyperphosphatemia drugs for the types as well as the applications to calculate the market size by considering 2017 as the base year.
Within this report from Triton on the global hyperphosphatemia drugs market, Porter’s five force model, key buying outlook, key insights, key market trends and guidance related to phosphate binders have been studied.
Market drivers like the growing prevalence of chronic diseases, increase in public cognizance and increase in the geriatric population have been analyzed. The industry is facing restraints like limitations levied by the Food and Drug Administration (FDA) and the growing side-effects of hyperphosphatemia drugs, which are obstructing the industry growth.
Key opportunities like the rising aging population can be leveraged by the industry to get towards the projected growth. However, non-adherence to treatment regiments, limited availability of drugs and the use of advanced dialysis techniques are the challenges facing the market at this moment.
To get detailed insights on segments, Download Sample Report
Geographies covered for the global hyperphosphatemia drugs market:
• North America: the United States and Canada
• Europe: the United Kingdom, Germany, France, Italy, Spain and Rest of Europe
• Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia and Rest of Asia-Pacific
• Latin America: Brazil, Mexico and Rest of Latin America
• The Middle East and Africa: the United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of Middle East & Africa
The global hyperphosphatemia drugs market is segmented into:
• By dosages:
O Solid
• Tablet
• Powder
O Liquid
• Solution
• By formulation:
O Calcium-based phosphate binders
O Aluminum-based phosphate binders
O Magnesium-based phosphate binders
O Iron-based phosphate binders
O Other phosphate binders
The top key players in the hyperphosphatemia drugs market are Royal DSM N.V., Sanofi, Bio-Tech Pharmacal, Fresenius Medical Care, Keryx Biopharmaceuticals, Inc., Roche Diagnostics Corporation, Shire, Fermenta Biotech, Ltd., Sun Pharmaceutical Industries, Ltd., Cipla, Pfizer, Inc., AMAG Pharmaceuticals, Johnson and Johnson, Bruno Farmaceutici S.p.A., Ultragenyx Pharmaceutical, Inc. and Zeria Pharmaceutical.
The strategic analysis for each of these companies has been covered in detail in the report. The company market share helps to dive into the information about the key market players in the industry and their corresponding hold in the market.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL
HYPERPHOSPHATEMIA DRUGS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. PORTER’S
FIVE FORCE MODEL
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. BARGAINING
POWER OF BUYERS
2.2.3. BARGAINING
POWER OF SUPPLIERS
2.2.4. THREAT
OF SUBSTITUTE PRODUCT
2.2.5. INTENSITY
OF COMPETITIVE RIVALRY
2.3. VENDOR
SCORECARD
2.4. KEY
BUYING OUTLOOK
2.5. KEY
INSIGHTS
2.6. KEY
MARKET TRENDS
2.7. GUIDELINES
RELATED TO THE PHOSPHATE BINDERS
2.8. MARKET
DRIVERS
2.8.1. CHRONIC
DISORDERS ARE INCREASING RAPIDLY
2.8.2. INCREASE
IN PUBLIC COGNIZANCE
2.8.3. INCREASE
IN GERIATRIC POPULATION
2.9. MARKET
RESTRAINTS
2.9.1. SIDE-EFFECTS
RELATED TO THE USAGE OF HYPERPHOSPHATEMIA DRUGS
2.9.2. STRICT
FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS
2.10.
MARKET OPPORTUNITIES
2.10.1.
RISE IN THE AGING POPULATION
2.11.
MARKET CHALLENGES
2.11.1.
ALTERNATIVE DIALYSIS
TECHNIQUES
2.11.2.
ACCESSIBILITY OF DRUGS IS
LIMITED
2.11.3.
NON-ADHERENCE TO TREATMENT
REGIMES
3. HYPERPHOSPHATEMIA
DRUGS MARKET OUTLOOK - BY DOSAGES
3.1. SOLID
3.1.1. TABLET
3.1.2. POWDER
3.2. LIQUID
3.2.1. SOLUTION
4. HYPERPHOSPHATEMIA
DRUGS MARKET OUTLOOK - BY FORMULATION
4.1.1. CALCIUM-BASED
PHOSPHATE BINDERS
4.1.2. ALUMINUM-BASED PHOSPHATE BINDERS
4.1.3. MAGNESIUM-BASED
PHOSPHATE BINDERS
4.1.4. IRON-BASED
PHOSPHATE BINDERS
4.1.5. OTHER
PHOSPHATE BINDERS
5. HYPERPHOSPHATEMIA
DRUGS INDUSTRY – REGIONAL OUTLOOK
5.1. NORTH
AMERICA
5.1.1. MARKET
BY FORMULATION
5.1.2. COUNTRY
ANALYSIS
5.1.2.1. UNITED
STATES
5.1.2.2. CANADA
5.2. EUROPE
5.2.1. MARKET
BY FORMULATION
5.2.2. COUNTRY
ANALYSIS
5.2.2.1. UNITED
KINGDOM
5.2.2.2. FRANCE
5.2.2.3. GERMANY
5.2.2.4. SPAIN
5.2.2.5. ITALY
5.2.2.6. RUSSIA
5.2.2.7. REST
OF EUROPE (ROE)
5.3. ASIA
PACIFIC
5.3.1. MARKET
BY FORMULATION
5.3.2. COUNTRY
ANALYSIS
5.3.2.1. INDIA
5.3.2.2. CHINA
5.3.2.3. JAPAN
5.3.2.4. AUSTRALIA
5.3.2.5. REST
OF APAC
5.4. LATIN
AMERICA
5.4.1. MARKET
BY FORMULATION
5.4.2. COUNTRY
ANALYSIS
5.4.2.1. BRAZIL
5.4.2.2. MEXICO
5.4.2.3. REST
OF LATIN AMERICA
5.5. MIDDLE
EAST AND AFRICA (MEA)
5.5.1. MARKET
BY FORMULATION
5.5.2. COUNTRY
ANALYSIS
5.5.2.1. SAUDI
ARABIA
5.5.2.2. TURKEY
5.5.2.3. UNITED
ARAB EMIRATES
5.5.2.4. SOUTH
AFRICA
5.5.2.5. REST
OF MIDDLE EAST AND AFRICA
6. COMPETITIVE
LANDSCAPE
6.1. JOHNSON
AND JOHNSON
6.2. ZERIA
PHARMACEUTICAL
6.3. AMAG
PHARMACEUTICALS
6.4. SANOFI
6.5. BRUNO
FARMACEUTICI S.P.A.
6.6. ROCHE
DIAGNOSTICS CORPORATION
6.7. ROYAL
DSM N.V.
6.8. SHIRE
6.9. CIPLA
6.10.
ULTRAGENYX PHARMACEUTICAL,
INC.
6.11.
FERMENTA BIOTECH, LTD.
6.12.
BIOTECH PHARMACAL
6.13.
SUN PHARMACEUTICAL INDUSTRIES,
LTD.
6.14.
KERYX BIOPHARMACEUTICALS, INC.
6.15.
FRESENIUS MEDICAL CARE
6.16.
PFIZER, INC.
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY
REGION 2019-2027 ($ MILLION)
TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS
TABLE 3 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY
FORMULATION 2019-2027 ($ MILLION)
TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF
CHRONIC KIDNEY DISEASE
TABLE 5 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS
MARKET BY FORMULATION 2019-2027 ($ MILLION)
TABLE 6 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET
COUNTRY ANALYSIS 2019-2027 ($ MILLION)
TABLE 7 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET BY
FORMULATION 2019-2027 ($ MILLION)
TABLE 8 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET
COUNTRY ANALYSIS 2019-2027 ($ MILLION)
TABLE 9 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS
MARKET BY FORMULATION 2019-2027 ($ MILLION)
TABLE 10 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS
MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)
TABLE 11 PER CAPITA CONSUMPTION OF DAIRY PRODUCTS
IN AUSTRALIA
TABLE 12 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS
MARKET BY FORMULATION 2019-2027 ($ MILLION)
TABLE 13 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS
MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)
TABLE 14 MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA
DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)
TABLE 15 MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA
DRUGS MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)
FIGURE 1 PORTER’S FIVE FORCE MODEL OF
HYPERPHOSPHATEMIA MARKET
FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL
STATUS 2014-2017
FIGURE 3 GLOBAL POPULATION AGED 80 AND ABOVE
1950-2050 (MILLION)
FIGURE 4 RATE OF ADHERENCE TO PHOSPHATE BINDERS
FIGURE 5 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN
CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 6 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN
ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 7 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN
MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN
IRON-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN
OTHER PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET SHARE
BY REGION 2018 & 2027 (%)
FIGURE 11 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 12 UNITED STATES HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 13 CANADA HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 14 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 15 UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 16 FRANCE HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 17 GERMANY HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 18 SPAIN HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 19 ITALY HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 20 RUSSIA HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 21 REST OF EUROPE HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 22 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 23 AGEWISE DISTRIBUTION OF ELDERLY POPULATION IN
INDIA
FIGURE 24 INDIA HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 25 CHINA HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 26 JAPAN HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 27 NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND
OSTEOPENIA
FIGURE 28 SOUTH KOREA HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 29 ASEAN COUNTRIESHYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 30 AUSTRALIA & NEW ZEALAND HYPERPHOSPHATEMIA
DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 31 ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 32 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 33 BRAZIL HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 34 MEXICO HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 35 REST OF LATIN AMERICA HYPERPHOSPHATEMIA DRUGS
MARKET 2019-2027 ($ MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA HYPERPHOSPHATEMIA
DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 37 SAUDI ARABIA HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 38 TURKEY HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 39 UNITED ARAB EMIRATES HYPERPHOSPHATEMIA DRUGS
MARKET 2019-2027 ($ MILLION)
FIGURE 40 SOUTH AFRICA HYPERPHOSPHATEMIA DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE 41 REST OF MIDDLE EAST & AFRICA
HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)